Crinetics Pharmaceuticals Inc [CRNX] stock is trading at $33.02, up 3.41%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRNX shares have gain 13.63% over the last week, with a monthly amount glided 2.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $36. Previously, Stifel started tracking the stock with Buy rating on March 25, 2025, and set its price target to $60. On February 11, 2025, TD Cowen initiated with a Buy rating. Wolfe Research started tracking the stock assigning a Peer Perform rating. Jefferies upgraded its rating to a Buy but $55 remained the price target by the analyst firm on January 22, 2025. Citigroup started tracking with a Buy rating for this stock on March 06, 2024, and assigned it a price target of $68. In a note dated January 16, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $50 on this stock.
Crinetics Pharmaceuticals Inc [CRNX] stock has fluctuated between $24.10 and $62.53 over the past year. Currently, Wall Street analysts expect the stock to reach $62.33 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $33.02 at the most recent close of the market. An investor can expect a potential return of 88.76% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at 0.01% with Operating Profit Margin at -495.7%, Pretax Profit Margin comes in at -431.91%, and Net Profit Margin reading is -431.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.31 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.22 points at the first support level, and at 31.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.61, and for the 2nd resistance point, it is at 34.19.
Ratios To Look Out For
For context, Crinetics Pharmaceuticals Inc’s Current Ratio is 22.53. Further, the Quick Ratio stands at 22.53, while the Cash Ratio is 1.65. Considering the valuation of this stock, the price to sales ratio is 8592.56, the price to book ratio is 2.46.
Transactions by insiders
Recent insider trading involved Betz Stephen F., Chief Scientific Officer, that happened on Jun 12 ’25 when 97483.0 shares were sold. Officer, STEPHEN BETZ completed a deal on Jun 12 ’25 to buy 97483.0 shares. Meanwhile, Chief Med and Dev Officer Pizzuti Dana sold 2515.0 shares on Mar 19 ’25.
